Atypical hemolytic-uremic syndrome: genes and variants
Explore variant evidence for Atypical hemolytic-uremic syndrome across 4 analyzed proteins (CFH, C3, HBB, C5). Linked ClinVar records include 18 pathogenic or likely pathogenic variants, 73 variants of uncertain significance and 16 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Atypical hemolytic-uremic syndrome
CFH: Complement factor H
It restrains the alternative complement pathway on host surfaces and in plasma, protecting tissues from uncontrolled complement amplification. Pathogenic variants or risk alleles are associated with atypical hemolytic uremic syndrome, C3 glomerulopathy, and age-related macular degeneration.
12 ClinVar pathogenic / likely pathogenic and 25 uncertain variants in CFH have source records linked to Atypical hemolytic-uremic syndrome. Association strength is not clinical gene validity.
C3: Complement C3
It is cleaved during complement activation to generate C3a and C3b, which amplify inflammation, opsonize targets, and drive formation of downstream complement complexes. Deficiency causes severe susceptibility to bacterial infection, while dysregulated activation contributes to complement-mediated kidney and inflammatory diseases.
5 ClinVar pathogenic / likely pathogenic and 63 uncertain variants in C3 have source records linked to Atypical hemolytic-uremic syndrome. Association strength is not clinical gene validity.
HBB: Hemoglobin subunit beta
Beta-globin, one of the two major protein chains in adult hemoglobin. Hemoglobin uses these chains to transport oxygen from the lungs to tissues, and HBB variants are associated with sickle-cell disease and beta-thalassemia.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in HBB have source records linked to Atypical hemolytic-uremic syndrome. Association strength is not clinical gene validity.
C5: Complement C5
Its cleavage produces the potent inflammatory mediator C5a and C5b, which initiates assembly of the membrane-attack complex. Excessive activation contributes to several complement-mediated disorders, making C5 blockade an established therapeutic strategy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in C5 have source records linked to Atypical hemolytic-uremic syndrome. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): COL4A4, ADAMTS13, COL4A3, COL4A5 and NPHS1.
Where Atypical hemolytic-uremic syndrome variants cluster
- CFH Sushi 20 (positions 1170–1230): 4 of 12 ClinVar pathogenic / likely pathogenic variants, 6.7× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Atypical hemolytic-uremic syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CFH W1183L | 1183 | Sushi 20 | Pathogenic / likely pathogenic (★★) |
| C3 R592W | 592 | Pathogenic / likely pathogenic (★★) | |
| C3 R592Q | 592 | Pathogenic / likely pathogenic (★★) | |
| CFH P1226S | 1226 | Sushi 20 | Pathogenic / likely pathogenic (★★) |
| CFH D1119G | 1119 | Sushi 19 | Pathogenic / likely pathogenic (★★) |
| C3 I1157T | 1157 | Pathogenic / likely pathogenic (★★) | |
| CFH W1183R | 1183 | Sushi 20 | Pathogenic / likely pathogenic (★) |
| C3 G1116R | 1116 | Pathogenic / likely pathogenic (★) | |
| CFH C431S | 431 | Sushi 7 | Pathogenic / likely pathogenic (★) |
| CFH C325Y | 325 | Sushi 6 | Pathogenic / likely pathogenic (★) |
| CFH C673Y | 673 | Sushi 11 | Pathogenic / likely pathogenic (★) |
| CFH W978C | 978 | Sushi 16 | Pathogenic / likely pathogenic (★) |
| CFH W1157R | 1157 | Sushi 19 | Pathogenic / likely pathogenic (★) |
| CFH C1163W | 1163 | Sushi 19 | Pathogenic / likely pathogenic (★) |
| CFH R1215G | 1215 | Sushi 20 | Pathogenic / likely pathogenic (★) |
| HBB L69P | 69 | Globin | Pathogenic / likely pathogenic (★) |
| C3 A1094V | 1094 | Pathogenic / likely pathogenic (★) | |
| CFH Y1021F | 1021 | Sushi 17 | Pathogenic / likely pathogenic (★) |
Uncertain variants prioritized for review in Atypical hemolytic-uremic syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CFH W1183C | 1183 | Sushi 20 | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; W1183L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
Which prediction tools work for Atypical hemolytic-uremic syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 94 out of 100
- ESM1b (LLR): 92 out of 100
- CATVariant: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 86 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 81 out of 100
- MetaSVM: 72 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 71 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Familial erythrocytosis also has ClinVar records linked to HBB variants; they fall mostly in different places as the Atypical hemolytic-uremic syndrome variants (31 pathogenic / likely pathogenic).
- Beta thalassemia also has ClinVar records linked to HBB variants; they fall mostly in different places as the Atypical hemolytic-uremic syndrome variants (21 pathogenic / likely pathogenic).
- Beta-thalassemia HBB/LCRB also has ClinVar records linked to HBB variants; they fall mostly in different places as the Atypical hemolytic-uremic syndrome variants (18 pathogenic / likely pathogenic).
- Heinz body anemia also has ClinVar records linked to HBB variants; they fall mostly in different places as the Atypical hemolytic-uremic syndrome variants (12 pathogenic / likely pathogenic).
- Hemoglobinopathy also has ClinVar records linked to HBB variants; they fall mostly in different places as the Atypical hemolytic-uremic syndrome variants (12 pathogenic / likely pathogenic).
Diseases related to Atypical hemolytic-uremic syndrome
- Age related macular degeneration, also linked to C3 and CFH
- Retinal disorder, also linked to C3 and CFH
- Familial erythrocytosis, also linked to HBB
- Malaria, also linked to HBB
- Beta thalassemia, also linked to HBB
- Heinz body anemia, also linked to HBB
- Beta-thalassemia HBB/LCRB, also linked to HBB
- Hemoglobinopathy, also linked to HBB
- Dominant beta-thalassemia, also linked to HBB
- Alpha Thalassemia, also linked to HBB
- Hemoglobin M disease, also linked to HBB
- Factor H deficiency, also linked to CFH
Frequently asked questions
Which genes have records linked to Atypical hemolytic-uremic syndrome?
This view contains 4 analyzed proteins: CFH, C3, HBB, C5. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 18 pathogenic or likely pathogenic variants, 73 variants of uncertain significance and 16 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 133 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center